Purpose and background for concluding this agreement
This agreement aims to secure a future revenue base through the commercialization of this biosimilar product, establish a solid financial base, and gain market share in the field of ophthalmologic diseases.
Aflibercept (product name: Eylea) is marketed as a treatment for age-related macular degeneration in
Kishi Kasei has the technology and know-how accumulated through the manufacturing and sale of colors for use in foods, cosmetics, medicines, and clinical testing reagents etc. By taking this advantages, Kishi Kasei has been developing and manufacturing drug substances for biological medicines, and achieved high track record. We believe Kishi Kasei is the best partner to build the manufacturing system of the drug substances for this biosimilar product.
Under this development agreement, we will establish a manufacturing process for the drug substance using high-yield protein producing cell lines. In parallel, we will search for a partner to jointly promote drug development, non-clinical studies, clinical studies, manufacturing and marketing approvals, sales, etc., and build business structure for a commercialization of this biosimilar product.
Contents of this agreement
Joint development agreement for a series of developments toward the commercialization of this biosimilar product using Aflibercept biosimilar producing cell line jointly developed with Fuso Pharmaceutical.
Outline of counterparties to this agreement (as of
Established May, 1953
Head Office 1-10-8 Fukuura, Kanazawa-ku,
Main Business Manufacture and marketing of colors for use in foods, cosmetics, medicines, and consumer products; clinical testing reagents and other acidic dyestuffs.
Capital
Future outlook
The impact on the business results for the fiscal year ending
About
GTS announced GTS 3.0 'Biotech Engineering Company, striving for value creation' a new business stage starting from this fiscal year, which targeted the pediatric disease in addition to the areas GTS has been engaged in such as the orphan disease and intractable disease. By leveraging the knowhow and expertise about biotechnology acquired in the past business activities, GTS is working on the development and provision of new medicines and therapeutic treatment for the purpose of achieving comprehensive healthcare solutions for the patients suffering from these diseases as well as families and caregivers.
Contact:
Tel: +81-3-6222-9547
Email: info@g-gts.com
(C) 2019 Electronic News Publishing, source